Application of A2 beta-casein to preparation of product for promoting gastrointestinal motility and digestive absorption

Abstract

The invention belongs to the technical field of protein application, and particularly relates to application of A2 beta-casein in preparation of products for promoting gastrointestinal motility and digestive absorption. The invention provides an application of A2 beta-casein in preparation of a product for promoting gastrointestinal motility and digestive absorption, which is characterized in that an animal in-vivo model and an in-vitro intestinal ectropion model are constructed, and differences of A1 beta-casein and A2 beta-casein in in-vivo digestive absorption and gastrointestinal motility processes are systematically compared; the A2 beta-casein is proved to have a better effect of promoting gastrointestinal motility and digestive absorption compared with A1 beta-casein, and an action mechanism of the A2 beta-casein in promoting gastrointestinal motility and digestive absorption is also disclosed; therefore, a scientific basis and a technical reference can be provided for development and application of A2 beta-casein in medicines, functional foods and health-care products.

Description

Technical Field

[0001] The present invention belongs to the technical field of protein application, and particularly relates to the application of A2β-casein in the preparation of products that promote gastrointestinal motility and digestion and absorption. Background Art

[0002] Milk is a natural food with nutritional proportions suitable for human needs and is easy to digest. It contains a variety of nutrients such as fat, protein, lactose, and inorganic salts. Among them, casein is the most abundant protein in cow's milk, accounting for approximately 80% of the total content. It is a protein with biological value and contains a high content of essential amino acids.

[0003] Studies have found that as one of the subtypes of casein, β-casein has amino acid differences at specific sites on the peptide chain, and 13 variants have been identified (A1, A2, A3, A4, B, C, D, E, F, G, H1, H2, I). Among them, A1β-casein and A2β-casein are the two most common variants. A2β-casein is considered to be the original genotype of milk. Due to gene mutation, the 67th amino acid on the polypeptide chain mutates from proline (Pro) to histidine (His), thus forming A1β-casein. Compared with proline, histidine is less likely to enter the substrate binding site of certain digestive enzymes, and due to the unique ring structure of proline, the binding of proline to isoleucine is more stable. Therefore, compared to the peptide bond Ile in A2β-casein 66 -Pro 67 , Ile in A1β-casein 66 -His 67 The bond is more susceptible to enzymatic hydrolysis to produce β-casomorphin-7, a peptide with opioid activity, which may have adverse effects on the human body, such as type 1 diabetes, indigestion, changes in stool consistency, cognitive dysfunction, and T cell-mediated inflammatory responses.

[0004] In recent years, A2 β-casein has garnered widespread attention due to its gut-friendly properties for lactose-intolerant patients and its similar composition to β-casein in breast milk. Existing studies have shown that A2 β-casein exhibits significant immunomodulatory properties, promoting splenic lymphocyte proliferation, significantly increasing macrophage phagocytic index and NK cell activity, and enhancing intestinal mucosal immune function. Studies have also found that A2 β-casein may possess superior functional properties compared to A1 β-casein, such as enhanced antioxidant capacity and lowering cholesterol levels.

[0005] However, most existing studies focus on the products of A1β-casein and A2β-casein after static in vitro digestion or on functional aspects such as immune regulation and lactose intolerance. However, in-depth research is still lacking on the specific differences between A1β-casein and A2β-casein in in vivo digestion and absorption, gastrointestinal motility, and their long-term effects on digestive system function. Summary of the Invention

[0006] To address the shortcomings of the prior art, the present invention aims to provide the use of A2 β-casein in the preparation of products that promote gastrointestinal motility and digestion and absorption. By constructing in vivo and in vitro intestinal eversion models, the present invention systematically compares the differences between A1 β-casein and A2 β-casein in digestion, absorption, and gastrointestinal motility. This study demonstrates that A2 β-casein exhibits superior effects in promoting gastrointestinal motility and digestion and absorption. This provides a scientific basis for the development and application of A2 β-casein in pharmaceuticals, functional foods, and health supplements.

[0007] To achieve the above object, the first aspect of the present invention adopts the following technical solution:

[0008] Use of A2β-casein in preparing products that promote gastrointestinal motility and / or digestion and absorption.

[0009] The second aspect of the present invention adopts the following technical solution:

[0010] A product for promoting gastrointestinal motility and / or digestion and absorption, comprising A2β-casein.

[0011] In a preferred embodiment of the present invention, in the product, the daily dosage of A2β-casein is 200 to 800 mg / kg body weight.

[0012] In a preferred embodiment of the present invention, in the product, the daily dose of A2β-casein is 500 mg / kg body weight.

[0013] In a preferred embodiment of the present invention, the product is a medicine, food or health product.

[0014] In a preferred embodiment of the present invention, the medicine is an oral preparation.

[0015] In a preferred embodiment of the present invention, the oral preparation is one or more of oral liquid, tablet, powder, capsule, and granule.

[0016] In a preferred embodiment of the present invention, the food is one or more of formula milk powder, modulated milk powder, and protein powder.

[0017] In a preferred embodiment of the present invention, the health product is a nutritional supplement.

[0018] In a preferred embodiment of the present invention, the product for promoting gastrointestinal motility and / or digestion and absorption further comprises an excipient. The present invention does not impose any particular limitation on the type of excipient, and skilled artisans may select the excipient appropriately based on product preparation requirements. In a preferred embodiment of the present invention, when the product is a medicine, food, or health product, the excipient may be selected from one or more of a filler, an adhesive, a colorant, a disintegrant, and a preservative.

[0019] The technical solution of the present invention has the following advantages and beneficial effects:

[0020] This study systematically compared the differences in digestion, absorption, and gastrointestinal motility between A1β-casein and A2β-casein by constructing in vivo and in vitro intestinal eversion models. The results confirmed that A2β-casein is superior to A1β-casein in promoting gastrointestinal motility and digestion and absorption. The study also revealed the mechanism of action of A2β-casein in promoting gastrointestinal motility and digestion and absorption. Therefore, this study can provide a scientific basis and technical reference for the development and application of A2β-casein in pharmaceuticals, functional foods, and health products, and has great promotional value. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The effects of A2β-casein and A1β-casein on loperamide-induced body weight (A), time to first black stool excretion (B), fecal water content (C), and small intestinal propulsion rate (D) in mice;

[0022] Figure 2 The results of the test on the levels of MTL (A), SP (B), GAS (C), VIP (D), SS (E) and ET (F) in the serum of mice induced by loperamide by A2β-casein and A1β-casein in the present invention are shown;

[0023] Figure 3 The morphological results of the mouse colon induced by loperamide were determined by H&E staining (magnification 200×) in the present invention;

[0024] Figure 4 The results are the absorption characteristics of protein digestion products measured in the in vitro intestinal eversion model of the present invention. DETAILED DESCRIPTION

[0025] In order to more clearly understand the above-mentioned objects, features and advantages of the present invention, the present invention is further described in detail below in conjunction with specific embodiments. It should be noted that, unless there is a conflict, the embodiments of the present invention and the features therein may be combined with each other, and the scope of protection of the present invention is not limited by the specific embodiments disclosed below.

[0026] In the following embodiments of the present invention, A1 milk and A2 milk are collected from four-year-old Australian imported Holstein and Jersey cows, respectively, on a ranch in Hebei Province. Loperamide hydrochloride, lactulose, and medical saline were purchased from Beijing Solaibao Technology Co., Ltd. All other raw materials, unless otherwise specified, are commercially available and commonly used in the art.

[0027] In the specific embodiments and test examples of the present invention, the preparation method of the A2β-casein used is as follows: 100 mL of A2 milk is taken as a milk sample, centrifuged at 5000 r / min for 25 minutes at 4°C to remove the milk fat in the milk, and then the pH value of the milk is adjusted to 4.6 with 1M hydrochloric acid, and allowed to stand for 35 minutes. After the obtained casein is neutrally washed, a dialysis bag with a molecular weight cutoff range of 8000-14000D is selected, and a 48-hour dialysis process is performed at a low temperature of 2-5°C. Fresh dialysate is promptly replaced every 7-8 hours to ensure the dialysis effect. After the dialysis steps are completed, the obtained casein solution is freeze-dried using a freeze dryer to obtain a crude casein extract. The crude casein extract is dissolved in mobile phase A to obtain a sample solution with a concentration of 10 mg / mL, first filtered with a 0.22 μm filter membrane to achieve sterilization, and then loaded for column chromatography purification. The mobile phase and gradient elution conditions were as follows: mobile phase A was an aqueous solution containing 4 M urea, 20 mM Tris, and 0.5 wt% mercaptoethanol, and mobile phase B was 1 M sodium chloride dissolved in mobile phase A. The gradient elution program was: 100% A at 0 min; 90% A, 10% B at 5 min; 80% A, 20% B at 10 min; and 70% A, 30% B at 15 min. The column volume was 5 mL, the sample load was 5 mL, the flow rate was 1 mL / min, the detection wavelength was 280 nm, and 4 mL of the purified protein solution was collected in a centrifuge tube. The resulting purified protein solution was lyophilized to obtain A2β-casein, which was stored at -20°C to ensure its stability until use.

[0028] In the specific embodiments and test examples of the present invention, the preparation method of A1 β-casein used is basically the same as the preparation method of A2 β-casein described above. The difference between the two methods is that A1 milk is used as the milk sample instead of A2 milk. The other preparation and purification steps are the same as the preparation method of A2 β-casein.

[0029] Example 1

[0030] This embodiment provides a product for promoting gastrointestinal motility and / or digestion and absorption, comprising A2β-casein. The product is a pharmaceutical, specifically a freeze-dried powder of A2β-casein. The daily dose of A2β-casein is 500 mg / kg body weight.

[0031] Test example

[0032] In the following experimental examples of the present invention, statistical analysis was performed using SPSS 0.05 software to analyze the data, mainly performing one-way analysis of variance and Tukey's test. The data are expressed as mean ± variance, and P < 0.05 was considered statistically significant.

[0033] 1. Test methods

[0034] 1.1 Animal model experiments on promoting gastrointestinal motility and digestion and absorption

[0035] Animal Model Establishment: Fifty SPF-grade female BALB / C mice, 6-7 weeks old and weighing 18-20 g, were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. All animal experimental procedures were approved by the Animal Ethics Committee of Northeast Agricultural University (No. NEAUEC20250401). All experimental animals were housed in an SPF-grade experimental animal room with constant pressure (18±2 Pa air), constant temperature (23±2°C), constant relative humidity (40-70%), and a 12-h light / dark cycle. Feed and water were added daily at 9:00 AM. Weight changes and activity levels of the mice were monitored. Bedding was changed every 5 days, and the mice were acclimated for 1 week. The mice were randomly divided into five groups (n=10 / group): a blank control group (NC group), a positive control group (PC group), a model group (MC group), an A1β-casein group (A1 group), and an A2β-casein group (A2 group). Except for the NC group, mice in the MC, PC, A1, and A2 groups were given loperamide hydrochloride (10 mg / kg mouse body weight) 5 hours before daily treatment to induce constipation. Furthermore, mice in the A1 and A2 groups were orally gavaged with the corresponding A1β-casein (500 mg / kg mouse body weight) and A2β-casein (500 mg / kg mouse body weight) daily. Mice in the PC group were treated with lactulose (70 mg / kg mouse body weight). Mice in the NC and MC groups were orally gavaged with an equal volume of normal saline daily. Each group received one gavage daily for 2 weeks. During the experiment, mice in each group had free access to food and water.

[0036] (1) Determination of the time of first black stool excretion and stool water content

[0037] Before the end of the experiment, three mice were randomly selected from each group after fasting for 12 hours (with free access to water) and individually placed in clean cages. One hour after the completion of the corresponding gavage sample, all mice in each group were gavaged with 0.2 mL of 5% charcoal suspension ink (5 g activated carbon + 1 g sodium carboxymethyl cellulose + 100 mL water). The gavage time and the time of the first black feces were recorded for each mouse. The time of the first black feces was the difference between the two gavage times. Fresh feces samples were collected into sterile tubes and placed in culture dishes in a constant temperature drying oven at 200°C for 120 min. The dry weight and wet weight of the fecal samples were recorded, and the fecal moisture content was calculated as (wet weight - dry weight) / wet weight × 100%. The mice were then killed by cervical dislocation.

[0038] (2) Determination of intestinal transit rate

[0039] The mesentery was separated from the intestinal lumen, and the small intestinal segment between the pylorus and the ileocecal junction was dissected, which was considered the entire small intestine. The small intestinal length and the distance from the pylorus to the ink border were measured. The distance from the pylorus to the ink border was considered the ink migration distance. The intestinal transit rate was calculated as = ink migration distance / total small intestinal length × 100%.

[0040] (3) Histomorphological study of the colon

[0041] After killing mice, the colon was dissected out and the flushed intestine was immersed in clean PBS. Approximately 5 mm long segments were excised and immediately fixed in 4% paraformaldehyde. After 48 hours, the tissues were embedded in paraffin, sectioned at approximately 4 μm thickness, and stained with hematoxylin and eosin (H&E). Morphological changes in the colon were observed using a light microscope at magnifications of 100 and 400.

[0042] (4) Determination of serum gastrointestinal regulatory peptides

[0043] Before sacrifice, blood was collected from the mice's eyes. After standing for 1 hour, the blood samples were centrifuged at 3000 rpm for 10 minutes at 4°C. Serum was separated and stored at -80°C for biochemical analysis. Levels of motilin (MTL), gastrin (GAS), somatostatin (SS), substance P (SP), vasoactive intestinal peptide (VIP), and endothelin (ET) were measured using ELISA kits according to the manufacturer's instructions.

[0044] 1.2. In vitro intestinal eversion model test

[0045] (1) Sample preparation

[0046] The solutions required to simulate adult gastrointestinal digestion in vitro were prepared as follows: Gastric juice: 0.5M KCl (6.9 mL) + 0.5M KH2PO4 (0.9 mL) + 1M NaHCO3 (12.5 mL) + 2M NaCl (11.8 mL) + 0.15M MgCl2(H2O)6 (0.4 mL) + 0.5M (NH4)2CO3 (0.5 mL). Distilled water was added to make the volume to 400 mL and incubated at 37°C for 30 minutes before the experiment. Intestinal juice: 0.5M KCl (6.8 mL) + 0.5M KH2PO4 (0.8 mL) + 1M NaHCO3 (42.5 mL) + 2M NaCl (9.6 mL) + 0.15M MgCl2(H2O)6 (1.1 mL). After adjusting the pH to 6.8, distilled water was added to make the volume to 500 mL and incubated at 37°C for 30 minutes before the experiment.

[0047] Test method: Take 12mL of gastric juice, add 7.5μL of 0.3M CaCl2 solution and 2% pepsin solution (enzyme: substrate = 1:50, 3000U / mg), each with 12mL of 1wt% A1β-casein solution, 1wt% A2β-casein solution, and deionized water, adjust the pH of the mixture to 2.5, place in an incubator (37°C, 130rpm) for 2h, and then remove to obtain gastric digestion fluid. Take 10mL of gastric digestion fluid and 10mL of intestinal fluid, add 1.8g of bile salts and 20μL of 0.3M CaCl2 solution, mix, add 4wt% trypsin (enzyme: substrate = 1:25, 250U / mL), adjust the pH to 7.0, and then add the mixed solution to the large test tube in the subsequent steps.

[0048] (2) Animal experiments

[0049] Experimental animals: SD rats; grade: SPF grade; weight: 180-220 g; age: 8 weeks; sex: male; certificate number: 20250216Aabbaabb01050000002; manufacturer: Hangzhou Ziyuan Experimental Animal Technology Co., Ltd.

[0050] Experimental Methods: Rats were fasted for 12 hours with free access to water. After cervical vertebrae sacrifice, the abdomen was opened and the small intestine was quickly removed. The intestinal segments were selected from the following locations: the duodenum was sampled 10 cm downward from 1 cm below the pylorus, the jejunum was sampled 10 cm downward from 15 cm from the pylorus, and the ileum was sampled 10 cm downward from 20 cm above the cecum. The mesentery and intestinal fat were removed and the intestine was washed 3-4 times in 4°C Krebs solution. The small intestine was then flipped and washed 3-4 times in 4°C Krebs solution to completely remove the intestinal contents. The tip of a hard glass tube (open at both ends) was inserted into the stump of the small intestine, and the stump was tied twice with cotton thread to form a sac-shaped intestinal tube. 1.8 mL of Krebs solution was injected into the serosal side of the intestinal tube through the wide end of the hard glass tube. After confirming that there was no leakage after the intestinal tube was turned over, the tube was inserted into the large test tube obtained in step (1). The entire device was placed in a 37°C constant temperature water bath and fixed. A mixed gas (5% CO2 + 95% O2) was continuously introduced through the air supply pump. 0.4 mL of mucosal fluid was collected by injection at four time points: 30 min, 60 min, 120 min, and 180 min. At the same time, 0.4 mL of 37°C Krebs buffer was added to each intestinal tube. Each sample was sealed and stored at -20°C until use. The protein (or polypeptide) content of the digestion solution and the absorption sample was determined.

[0051] The protein absorption rate formula is as follows: Wherein, P1 is the protein content in the digestion solution (mg / mL); P2 is the protein content in the culture solution (mg / mL); and P0 is the protein content in the blank (mg / mL).

[0052] 2. Test results

[0053] 2.1 Effects of A1β-casein / A2β-casein on body weight, fecal parameters, and small intestinal propulsion rate

[0054] Weight change is an important indicator of overall mouse health. Fecal moisture content, time to first black stool, and small intestinal propulsion rate can reflect intestinal transit rate, water absorption and secretion, and intestinal motility. Figure 1 The figures show the effects of A2β-casein and A1β-casein on the body weight (A), the time of first black stool discharge (B), the water content of stool (C) and the small intestinal propulsion rate (D) of mice. Figure 1 Different letters indicate significant differences (P<0.05). NC is the normal control group, PC is the positive control group, MC is the model control group, A1 is the A1β-casein group, and A2 is the A2β-casein group.

[0055] Figure 1Compared with the NC group, the body weight of MC mice was significantly reduced (P < 0.05), while the other groups showed significant differences (P < 0.05). After β-casein treatment, the body weight of mice in group A2 approached that of the PC group, while the weight gain of mice in group A1 was significantly less than that of mice in group A2 (P < 0.05). This indicates that A1β-casein and A2β-casein have a positive effect on weight restoration, with A2β-casein being significantly more effective than A1β-casein (Figure A). Furthermore, compared with the NC group, the fecal water content and small intestinal propulsion rate of the MC group were significantly reduced (P < 0.05), while the time to first black stool was significantly increased (P < 0.05), prolonging intestinal transit time and confirming the successful establishment of the model. After treatment with A1β-casein and A2β-casein, mice in group A2 showed significant improvements in all parameters (P < 0.05), with the improvement in time to first black stool comparable to that of the PC group, shortening it to 195-213 minutes. In contrast, although mice in the A1 group also showed some improvement, the effect was not as significant as that in the A2 group (P<0.05), and there was no statistically significant difference in fecal moisture content (21.6±1.10%) compared to the MC group (19.70±1.70%) (Figures B, C, and D). This suggests that both A1β-casein and A2β-casein have an ameliorative effect on constipated mice, primarily by promoting weight recovery, improving intestinal transit function, and improving fecal characteristics. Furthermore, A2β-casein may promote intestinal motility by increasing fecal moisture content.

[0056] 2.2 Effects of A1β-casein / A2β-casein on serum gastrointestinal regulatory peptides

[0057] Motilin (MTL), substance P (SP), and gastrin (Gas) are key excitatory neurotransmitters, while vasoactive intestinal peptide (VIP), somatostatin (SS), and endothelin (ET) act as inhibitory neurotransmitters. Both types of neurotransmitters play a key role in regulating gastrointestinal motility. To elucidate the mechanism by which A1β-casein / A2β-casein affect gastrointestinal motility, serum levels of these neurotransmitters were measured. Figure 2 Figure 3. Serum MTL (A), SP (B), GAS (C), VIP (D), SS (E), and ET (F) levels in loperamide-induced mice treated with A1β-casein / A2β-casein. Different letters indicate significant differences (P < 0.05).

[0058] like Figure 2As shown, regarding MTL, the content was significantly reduced in constipated mice (134.28 pg / mL in the model group) compared with the blank group (303.28 pg / mL in the control group). The A2 group significantly increased MTL to 219.76 pg / mL, while mice treated with lactose (291.22 pg / mL in the PC group) maintained a level comparable to that of the NC group (Figure A). In addition, A1β-casein / A2β-casein significantly increased SP levels (209.78 pg / mL in the A1 group, 273.05 pg / mL in the A2 group, and 175.92 pg / mL in the MC group) (Figure B). Gas levels in constipated mice (28.03 pg / mL in the MC group) were significantly lower than those in the control group (62.08 pg / mL in the NC group). Gas levels were significantly increased in the A1 group (40.30 pg / mL), the A2 group (52.7 pg / mL), and the PC lactose group (60.58 pg / mL) (Figure C). Compared with the control group, constipated mice showed significantly higher levels of VIP (215.51 pg / mL in the MC group and 118.46 pg / mL in the NC group), SS (47.07 pg / mL in the MC group and 12.04 pg / mL in the NC group), and ET (148.56 pg / mL in the MC group and 82.86 pg / mL in the NC group) (Figures D, E, and F). This suggests that loperamide affects the production of neurotransmitters, which may be related to the pathogenesis of intestinal motility disorders. A1β-casein and A2β-casein help restore normal gastrointestinal motility by increasing excitatory neurotransmitter levels and decreasing inhibitory neurotransmitter levels. A2β-casein, in particular, demonstrates greater efficacy in restoring excitatory neurotransmitters and promoting intestinal motility.

[0059] 2.3 Effects of A1β-casein / A2β-casein on colonic histological morphology

[0060] The structural integrity and pathological changes of colon tissue were evaluated by H&E staining. Figure 3 shown.

[0061] Figure 3In the NC group, colonic tissue was intact, with visible and normal goblet cells, normal submucosal structure, and no edema. The PC group showed mild histological changes, including slight thickening of the mucosal layer and mild infiltration of inflammatory cells in the lamina propria, but these changes were not significant. In the MC group, focal crypt structure in the lamina propria was lost, and lymphoid tissue hyperplasia with lymphoid follicle formation, lymphoid nodules, and intraluminal congestion were observed. Muscle tissue was thin, the submucosal layer was loose and edematous, the number of goblet cells was reduced, and there was significant infiltration of inflammatory cells in the lamina propria. These changes indicate that constipation has damaged colonic tissue. In contrast, staining results in groups A1 and A2 showed varying degrees of histopathological improvement compared to the model group, with the A2 group showing more significant improvement, as evidenced by near-normal mucosal structure, restored goblet cell numbers, and a significant reduction in inflammatory cell infiltration. This suggests that A2β-casein helps maintain the integrity and function of the intestinal mucosa, thereby alleviating the inflammatory response.

[0062] 2.4 Study on the Absorption Characteristics of A1β-Casein / A2β-Casein

[0063] By constructing an in vitro intestinal eversion model, the effects of A1β-casein / A2β-casein on digestion and absorption were evaluated. Figure 4 shown. Figure 4 Different letters indicate significant differences (P<0.05).

[0064] Figure 4 In the duodenum and jejunum, the absorption rates of protein digestion products were approximately equal, with the lowest absorption rate in the ileum. However, among the three components, the absorption rate of A2β-casein digestion products was consistently higher than that of A1β-casein, suggesting that A2β-casein structurally or functionally facilitates protein digestion and absorption. In the duodenum and jejunum, significant differences were observed between the A1 and A2 groups (P < 0.05), with the A2 group having a higher absorption rate. This suggests that both groups have a positive effect on enhancing protein absorption in the duodenum and jejunum, with A2β-casein having a superior effect than A1β-casein, possibly due to its easier breakdown into small peptides during digestion. In the ileum, no significant differences were observed between the A1 and A2 groups (P > 0.05), but A2β-casein showed a higher absorption rate, which decreased in the ileum, suggesting that most of the protein digestion products may have been absorbed in the duodenum and jejunum. This shows that when protein is rapidly digested into low molecular weight (MW) peptides and amino acids, the main absorption occurs in the duodenum and lower jejunum. Increasing casein in the diet will lead to an increase in the content of low molecular weight peptides in the duodenum, and compared with A1β-casein, the use of A2β-casein is more conducive to promoting the body's digestion and absorption function.

[0065] In summary, the present invention systematically compares the differences in digestion and absorption of A1β-casein and A2β-casein in the process of gastrointestinal motility in vivo by constructing an in vivo animal model and an in vitro intestinal eversion model. At the same time, it confirms that A2β-casein has a better effect in promoting gastrointestinal motility and digestion and absorption than A1β-casein, and also reveals the mechanism of action of A2β-casein in promoting gastrointestinal motility and digestion and absorption. Therefore, it can provide a scientific basis for the development and application of A2β-casein in medicines, functional foods and health products, and has good promotion value.

[0066] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein; and these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. Use of A2 β-casein in the preparation of products for promoting gastrointestinal motility and / or digestion and absorption.

2. A product for promoting gastrointestinal motility and / or digestion and absorption, characterized in that: Contains A2 beta-casein.

3. The product for promoting gastrointestinal motility and / or digestion and absorption according to claim 2, characterized in that: In the product, the daily dosage of A2 β-casein is 200-800 mg / kg body weight.

4. The product for promoting gastrointestinal motility and / or digestion and absorption according to claim 3, characterized in that: In the product, the daily dosage of A2 β-casein is 500 mg / kg body weight.

5. The product for promoting gastrointestinal motility and / or digestion and absorption according to claim 2, characterized in that: The product is a medicine, food or health product.

6. The product for promoting gastrointestinal motility and / or digestion and absorption according to claim 5, characterized in that: The medicine is an oral preparation.

7. The product for promoting gastrointestinal motility and / or digestion and absorption according to claim 6, characterized in that: The oral preparation is one or more of oral liquid, tablet, powder, capsule, and granule.

8. The product for promoting gastrointestinal motility and / or digestion and absorption according to claim 5, characterized in that: The food is one or more of formula milk powder, modulated milk powder and protein powder.

9. The product for promoting gastrointestinal motility and / or digestion and absorption according to claim 5, characterized in that: The health care product is a nutritional supplement.

10. The product for promoting gastrointestinal motility and / or digestion and absorption according to claim 2, characterized in that: The product for promoting gastrointestinal motility and / or digestion and absorption further comprises auxiliary materials.

Images